Not all medicines and/or indications presented in this report may be approved for use in all countries. Please note data included in this report are based on EU data and may vary depending on local ...

But following exposure to endocrine and CDK4/6 inhibitor therapy, many patients quickly acquire ER mutations (ESR1m), leading to treatment resistance and leaving a significant unmet need.

But following exposure to endocrine and CDK4/6 inhibitor therapy, many patients quickly acquire ER mutations (ESR1m), leading to treatment resistance and leaving a significant unmet need. Pfizer’s and ...